

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 29 Feb 2020 23:40:04 +0000
To: Tom Leopold
Cc: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: ? ALTERNATIVE/SUPPLEMENTAL rx for COVID-19: Angiotensin Receptor Blockers

I have received this message and we are in fact looking into this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Tom Leopold (b) (6)>
Sent: Saturday, February 29, 2020 4:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: ? ALTERNATIVE/SUPPLEMENTAL rx for COVID-19: Angiotensin Receptor Blockers

Much appreciation for all of your work past and present. I am a cardiologist in New Jersey and when I read that the virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or mitigate the severity of infection. Has this approach ever been studied and is it worth looking into? Imagine if ARBs could lessen the severity of infection how readily available and relatively inexpensive this class of medication is! Would appreciate if someone could get back to inform me whether you received this message. Thanks. Dr Thomas Leopold Email: (b) (6)

Sent from my iPhone